Creative Planning’s Enzymotec Ltd ENZY Stock Holding History

Creative Planning’s Portfolio ENZY Stock Details ENZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-200	Closed	-$1K	–	5074
2016 Q4	$1K	Buy	+200	New	+$1.32K	﹤0.01%	4569

Other funds holding ENZY

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return

Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Creative Planning's ENZY Position: Q1 2017 in Review

Creative Planning sold out of Enzymotec Ltd (ENZY) in Q1 2017, closing a stake of 200 shares — an estimated $1K sold.

Creative Planning first reported a position in ENZY in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 26 funds tracked by Wall St. Rank hold ENZY as of Q1 2017.

Creative Planning reported no remaining Enzymotec Ltd position as of Q1 2017 after selling out during the quarter.
Creative Planning sold 200 Enzymotec Ltd shares in Q1 2017, an estimated $1K.
Creative Planning first reported a position in Enzymotec Ltd in Q4 2016 and held it in 1 quarter.
Creative Planning's Enzymotec Ltd position peaked at $1K in Q4 2016.
26 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q1 2017.

Based on Creative Planning's 13F filing for Q1 2017, filed 7 Apr 2017.